Suven Life Sciences Ltd (SUVEN) announces that two product patents were granted in China (100378108 and 100378109) and Russia (2325392 and 2340619) corresponding to two of their new chemical entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases and these patents are valid until 2023 and 2024 respectively.
The details can be read here.
No comments:
Post a Comment